Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma

Transfusion

Volumn 54, Issue 2, 2014, Pages 331-339

  Lanza, Francesco ^a   Lemoli, Roberto M ^a   Olivieri, Attilio ^a   Laszlo, Daniele ^a   Martino, Massimo ^a   Specchia, Giorgina ^a   Pavone, Vincenzo ^a   Imola, Manuela ^a   Pasini, Annalisa ^a   Milone, Giuseppe ^a   Scortechini, Ilaria ^a   Todisco, Elisabetta ^a   Guggiari, Elena ^a   Cascavilla, Nicola ^a   Martinelli, Giovanni ^a   Rambaldi, Alessandro ^a   Bosi, Alberto ^a  

^a CREMONA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; BLOOD COMPONENT REMOVAL; CHEMORADIOTHERAPY; DATA COLLECTION; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; ITALY; LEUKAPHERESIS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, CXCR4; YOUNG ADULT;

EID: 84894066812     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12265     Document Type: Article

References (23)

1. Rosenbeck LL, Srivastava S, Kiel PJ,. Peripheral blood stem cell mobilization tactics. Ann Pharmacother 2010; 44: 107-116.
2. Jantunen E, Fruehauf S,. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011; 46: 627-635.
3. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, Van Besien K, Dipersio J,. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50: 1412-1421.
4. Bensinger W, DiPersio JF, McCarty JM,. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-195.
5. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF,. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
6. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Durie BG, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904-1912.
7. Han X, Ma L, Zhao L, He X, Liu P, Zhou S, Yang J, Qin Y, Yang S, Yao J, Shi Y,. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. J Clin Apher 2012; 27: 64-74.
8. Duarte RF, Shaw BE, Marin P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martinez-Chamorro C, Mateos-Mazon JJ, Ramirez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH,. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52-58.
9. Hubel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, Jaksic O, Koristek Z, Kroger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF,. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 2012; 47: 1046-1050.
10. Malard F, Kroger N, Gabriel IH, Hubel K, Apperley JF, Basak GW, Douglas KW, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF,. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012; 18: 314-317.
11. Duong HK, Bolwell BJ, Rybicki L, Koo A, Hsi ED, Figueroa P, Dean R, Pohlman B, Kalaycio M, Andresen S, Sobecks R, Copelan E,. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. J Clin Apher 2011; 26: 111-115.
12. Keating GM,. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 2011; 71: 1623-1647.
13. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
14. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
15. Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E,. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. Leuk Res 2011; 35: 712-714.
16. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G,. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338.
17. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT,. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011; 51: 968-975.
18. Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J, Masszi T, Giebel S, Labar B, Wiktor-Jedrzejczak W,. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 2011; 86: 488-495.
19. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopetzky G, Soutar R, Casadei B, Baccarani M, Lemoli RM,. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-363.
20. Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A,. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18: 241-249.
21. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, Rambaldi A, Bosi A,. Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47: 342-351.
22. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
23. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G,. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-1586.